Mutational Landscape of Patients Treated With TG4050, an Individualised Neoantigen Therapeutic Vaccine In Early-Stage Cancer Treatment
- Phase 1 study of a viral-vectored individualised neoantigen vaccine in HNSCC
- Dive deeper into the mutational landscape of the patient population and factors influencing vaccine composition
- Immunogenicity of vaccine neoantigens and potential validation of bioinformatic prediction approach